With reference to its letter dated August 12, 2021 informing about the approval of the Scheme of Amalgamation by the Board of Director of the Company, providing for the amalgamation of wholly owned subsidiaries of the Company, Auronext Pharma and Mviyes Pharma Ventures with the Company subject to the requisite statutory I regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). Aurobindo Pharma has informed that since there were other restructuring proposals in discussion, this amalgamation was put on hold and now, the Board of Directors of the Company at its meeting held on April 1, 2023 has decided to proceed with the aforesaid Scheme of Amalgamation. The company has enclosed the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular NO.CIR/CFD/CMD/4/2015 dated September 9, 2015 in Annexure A to this letter.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: